Drugs that contain Meropenem; Vaborbactam
1. List of Vabomere drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(8 years from now) | |
| US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(8 years from now) | |
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 29, 2027 |
NCE-1 date: August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic